The advent of a novel manufacturing technology in pharmaceutics: superiority of fused deposition modeling 3D printer

Joo, Yechan; Shin, Intaek; Ham, Gunjoo; Abuzar, Sharif Md; Hyun, Sang Min; Hwang, Sung Joo

doi:10.1007/s40005-019-00451-1

Cited by 36 publications

(18 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FDM, a technology developed in the late 1980s, is also one of the most widely studied technologies in pharmaceutics. This technology, based on material extrusion, involves melting of filaments and deposition of the melted materials in layers where they fuse together to fabricate a 3D structure [4,13]. For this method, the materials used should be thermostable, non-volatile and non-aerosolizing [14].…”

Section: Introductionmentioning

confidence: 99%

Customized Novel Design of 3D Printed Pregabalin Tablets for Intra-Gastric Floating and Controlled Release Using Fused Deposition Modeling

et al. 2019

View full text Add to dashboard Cite

Three-dimensional (3D) printing has been recently employed in the design and formulation of various dosage forms with the aim of on-demand manufacturing and personalized medicine. In this study, we formulated a floating sustained release system using fused deposition modeling (FDM). Filaments were prepared using hypromellose acetate succinate (HPMCAS), polyethylene glycol (PEG 400) and pregabalin as the active ingredient. Cylindrical tablets with infill percentages of 25%, 50% and 75% were designed and printed with the FDM printer. An optimized formulation (F6) was designed with a closed bottom layer and a partially opened top layer. Filaments and tablets were characterized by means of fourier-transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD), and thermogravimetric analysis (TGA). The results show that the processing condition did not have a significant effect on the stability of the drug and the crystallinity of the drug remained even after printing. A dissolution study revealed that drug release is faster in an open system with low infill percentage compared to closed systems and open systems with a high infill ratio. The optimized formulation (F6) with partially opened top layer showed zero-order drug release. The results show that FDM printing is suitable for the formulation of floating dosage form with the desired drug release profile.

show abstract

Section: Introductionmentioning

confidence: 99%

Customized Novel Design of 3D Printed Pregabalin Tablets for Intra-Gastric Floating and Controlled Release Using Fused Deposition Modeling

et al. 2019

View full text Add to dashboard Cite

show abstract

“…There are several review articles published on extrusion-based 3D printing [11,[41][42][43][44][45][46][47][48][49][50][51]. However, those published articles focused on different aspects of this technology.…”

Section: Introductionmentioning

confidence: 99%

“…Vithani et al discussed potential opportunities for the 3D printing of soft materials such as lipids [48]. Joo et al discussed different FDM process and parameters and discussed how FDM 3D printers can be used to control the release, make a novel dosage form, and deliver the customized doses [49]. Long et al discussed appropriate polymers and key parameters required for FDM 3D printing and its usage in the printing of personalized tablets and drug delivery devices [50].…”

Section: Introductionmentioning

confidence: 99%

Polymers for Extrusion-Based 3D Printing of Pharmaceuticals: A Holistic Materials–Process Perspective

et al. 2020

View full text Add to dashboard Cite

Three dimensional (3D) printing as an advanced manufacturing technology is progressing to be established in the pharmaceutical industry to overcome the traditional manufacturing regime of 'one size fits for all'. Using 3D printing, it is possible to design and develop complex dosage forms that can be suitable for tuning drug release. Polymers are the key materials that are necessary for 3D printing. Among all 3D printing processes, extrusion-based (both fused deposition modeling (FDM) and pressure-assisted microsyringe (PAM)) 3D printing is well researched for pharmaceutical manufacturing. It is important to understand which polymers are suitable for extrusion-based 3D printing of pharmaceuticals and how their properties, as well as the behavior of polymer–active pharmaceutical ingredient (API) combinations, impact the printing process. Especially, understanding the rheology of the polymer and API–polymer mixtures is necessary for successful 3D printing of dosage forms or printed structures. This review has summarized a holistic materials–process perspective for polymers on extrusion-based 3D printing. The main focus herein will be both FDM and PAM 3D printing processes. It elaborates the discussion on the comparison of 3D printing with the traditional direct compression process, the necessity of rheology, and the characterization techniques required for the printed structure, drug, and excipients. The current technological challenges, regulatory aspects, and the direction toward which the technology is moving, especially for personalized pharmaceuticals and multi-drug printing, are also briefly discussed.

show abstract

“…Personalized medication has received attention from the medical society because of different drug effects caused by genetic background [ 1 ]. Current pharmaceutical manufacturing is based on mass production which produces pharmaceutical dosage forms with small variations in doses and API release profiles [ 2 ]. Because of such low flexibility, there are few options to adjust doses for individualized pharmacotherapy such as dosing liquid and dividing dosage forms into small units.…”

Section: Introductionmentioning

confidence: 99%

Hot-Melt 3D Extrusion for the Fabrication of Customizable Modified-Release Solid Dosage Forms

et al. 2020

View full text Add to dashboard Cite

In this work, modified-release solid dosage forms were fabricated by adjusting geometrical properties of solid dosage forms through hot-melt 3D extrusion (3D HME). Using a 3D printer with air pressure driving HME system, solid dosage forms containing ibuprofen (IBF), polyvinyl pyrrolidone (PVP), and polyethylene glycol (PEG) were printed by simultaneous HME and 3D deposition. Printed solid dosage forms were evaluated for their physicochemical properties, dissolution rates, and floatable behavior. Results revealed that IBF content in the solid dosage form could be individualized by adjusting the volume of solid dosage form. IBF was dispersed as amorphous state with enhanced solubility and dissolution rate in a polymer solid dosage form matrix. Due to absence of a disintegrant, sustained release of IBF from printed solid dosage forms was observed in phosphate buffer at pH 6.8. The dissolution rate of IBF was dependent on geometric properties of the solid dosage form. The dissolution rate of IBF could be modified by merging two different geometries into one solid dosage form. In this study, the 3D HME process showed high reproducibility and accuracy for preparing dosage forms. API dosage and release profile were found to be customizable by modifying or combining 3D modeling.

show abstract

The advent of a novel manufacturing technology in pharmaceutics: superiority of fused deposition modeling 3D printer

Cited by 36 publications

References 69 publications

Customized Novel Design of 3D Printed Pregabalin Tablets for Intra-Gastric Floating and Controlled Release Using Fused Deposition Modeling

Customized Novel Design of 3D Printed Pregabalin Tablets for Intra-Gastric Floating and Controlled Release Using Fused Deposition Modeling

Polymers for Extrusion-Based 3D Printing of Pharmaceuticals: A Holistic Materials–Process Perspective

Hot-Melt 3D Extrusion for the Fabrication of Customizable Modified-Release Solid Dosage Forms

Contact Info

Product

Resources

About